Pfizer Sees Unusually High Options Volume (NYSE:PFE)

Key Points

• Traders bought 254,818 call options on Pfizer on Thursday, an 84% increase versus the typical daily call volume, signaling unusually high speculative or hedging interest in the stock.
• Pfizer beat Q1 expectations with $0.75 EPS and $14.45B revenue, and reaffirmed FY2026 guidance of 2.80–3.00 EPS, supporting the view that newer medicines and oncology momentum are offsetting COVID-era declines.
• The company declared a quarterly dividend of $0.43 (annualized $1.72) implying a ~6.5% yield with an ex-dividend date of May 8, though the payout ratio is high at 131%, raising sustainability considerations.

Pfizer Inc. (NYSE:PFE - Get Free Report) was the target of unusually large options trading activity on Thursday. Traders acquired 254,818 call options on the company. This is an increase of 84% compared to the typical daily volume of 138,504 call options.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Daiwa Securities Group lowered shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. Royal Bank Of Canada reaffirmed an "underperform" rating and issued a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. BMO Capital Markets reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday, March 24th. Finally, CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an "outperform" rating and a $33.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average price target of $28.74.

Pfizer Stock Performance

PFE stock traded down $0.05 during mid-day trading on Thursday, reaching $26.48. 48,216,503 shares of the stock traded hands, compared to its average volume of 42,952,375. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer has a 52 week low of $21.97 and a 52 week high of $28.75. The business has a 50-day moving average of $27.16 and a two-hundred day moving average of $26.14. The firm has a market capitalization of $150.56 billion, a PE ratio of 20.21 and a beta of 0.35.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.48%. The company had revenue of $14.45 billion during the quarter, compared to analysts' expectations of $13.84 billion. During the same period in the prior year, the company earned $0.92 earnings per share. The business's quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer will post 2.97 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date is Friday, May 8th. Pfizer's dividend payout ratio is 131.30%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently bought and sold shares of PFE. Y Intercept Hong Kong Ltd acquired a new position in Pfizer in the third quarter worth about $3,019,000. Money Concepts Capital Corp raised its position in Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock worth $6,325,000 after purchasing an additional 57,188 shares in the last quarter. Kepler Cheuvreux Suisse SA acquired a new position in Pfizer in the third quarter worth about $16,613,000. Penn Davis Mcfarland Inc. raised its position in Pfizer by 50.9% in the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company's stock worth $4,266,000 after purchasing an additional 57,777 shares in the last quarter. Finally, Callahan Advisors LLC raised its position in Pfizer by 6.5% in the third quarter. Callahan Advisors LLC now owns 713,797 shares of the biopharmaceutical company's stock worth $18,188,000 after purchasing an additional 43,454 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 results beat and guidance reaffirmed — Pfizer reported Q1 revenue of $14.45B and EPS of $0.75 (both above expectations) and reaffirmed FY26 guidance, supporting the view that newer medicines are offsetting COVID-era declines. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Oncology momentum — recent milestones include FDA approval of VEPPANU (first PROTAC degrader approval) and positive Phase 3 data for ELREXFIO in multiple myeloma, which materially strengthen Pfizer’s oncology franchise and longer-term growth narrative. Pfizer Oncology Advances Raise New Questions For Valuation And Momentum
• Positive Sentiment: Dividend durability — coverage pieces argue Pfizer’s ~6.5% yield is sustainable after management commentary and results, reducing fears of a yield trap and supporting income-focused buyers. Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics
• Neutral Sentiment: Lyme vaccine update — Pfizer is running an extra/fifth-dose VLA15 trial; the move signals continued investment in the program but creates uncertainty on final labeling/dosing and commercial timing. Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors
• Neutral Sentiment: Share-shelf / employee offering noted — Pfizer filed a large employee share offering shelf registration (~$8.4B referenced in coverage). That supports compensation/liquidity plans but raises watchfulness for potential dilution. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Neutral Sentiment: Analyst views mixed — recent coverage shows conflicting analyst sentiments on valuation and momentum; this contributes to choppy intraday trading as investors sort thesis changes. Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Compass Therapeutics (CMPX)
• Negative Sentiment: Trial termination trims oncology upside — Pfizer ended a Phase 1b/2 lymphoma combo trial, which reduces near-term clinical-option value in that program and tempers some enthusiasm about oncology pipeline expansion. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.